<DOC>
	<DOCNO>NCT01297491</DOCNO>
	<brief_summary>The purpose two-stage phase II study ass efficacy BKM120 , measure determine progression free survival ( PFS ) , patient pretreated metastatic Non-small Cell Lung Cancer ( NSCLC ) exhibit PI3K pathway activation . BKM120 investigate two group NSCLC patient accord histology cancer : squamous non-squamous .</brief_summary>
	<brief_title>Safety Efficacy BKM120 Patients With Metastatic Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically confirm NSCLC activate PI3K pathway Progressive disease prior systemic antineoplastic treatment ( ) advance NSCLC Archival fresh tumor biopsy must available profile Measurable and/or nonmeasurable disease per RECIST 1.1 criterion Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Adequate organ function assess laboratory test Patient receive previous treatment PI3K inhibitor Patient squamous NSCLC receive one line chemotherapy treatment metastatic disease ; patient nonsquamous NSCLC receive two line systemic antineoplastic treatment metastatic disease Uncontrolled symptomatic CNS metastasis Concurrent use approve investigational antineoplastic agent Radiotherapy ≤ 28 day prior start study drug Major surgery within 28 day prior start study drug History clinically significant cardiac dysfunction , mood disorder , poorly control diabetes mellitus Current treatment medication know risk prolong QT interval induce Torsades de Pointes Impairment gastrointestinal ( GI ) function Chronic treatment steroid another immunosuppressive agent . Concurrent severe and/or uncontrolled medical condition Currently receive Warfarin another coumarin derivative Known history HIV infection Sensory neuropathy functional impairment ( CTC grade 2 neuropathy , regardless causality ) Pregnancy , lactation , breastfeed Woman childbearing potential Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>PI3K</keyword>
</DOC>